Dimitrios VELISSARIS

Prof. Dimitrios VELISSARIS

University of Patras, Pátrai, Greece

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
Nicholas KounisNicholas Kounis
Nicholas Kounis
IKIoanna C. Koniari
Ioanna C. Koniari
Cesare de GregorioCesare de Gregorio
Cesare de Gregorio
DVDimitris Velissaris
Dimitris Velissaris
KPKonstantinos Petalas
Konstantinos Petalas
Ming-Yow HungMing-Yow Hung
Ming-Yow Hung
Vaccines constitute the most effective medications in public health as they control and prevent the spread of infectious diseases and reduce mortality. Similar to other medications, allergic reactions can occur during vaccination. While most reactions are neither frequent nor serious, anaphylactic reactions are potentially life-threatening allergic reactions that are encountered rarely, but can cause serious complications. The allergic responses caused by vaccines can stem from activation of mast cells via Fcε receptor-1 type I reaction, mediated by the interaction between immunoglobulin E (IgE) antibodies against a particular vaccine, and occur within minutes or up to four hours. The type IV allergic reactions initiate 48 h after vaccination and demonstrate their peak between 72 and 96 h. Non-IgE-mediated mast cell degranulation via activation of the complement system and via activation of the Mas-related G protein-coupled receptor X2 can also induce allergic reactions. Reactions are more often caused by inert substances, called excipients, which are added to vaccines to improve stability and absorption, increase solubility, influence palatability, or create a distinctive appearance, and not by the active vaccine itself. Polyethylene glycol, also known as macrogol, in the currently available Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines, and polysorbate 80, also known as Tween 80, in AstraZeneca and Johnson & Johnson COVID-19 vaccines, are excipients mostly incriminated for allergic reactions. This review will summarize the current state of knowledge of immediate and delayed allergic reactions in the currently available vaccines against COVID-19, together with the general and specific therapeutic considerations. These considerations include: The incidence of allergic reactions and deaths under investigation with the available vaccines, application of vaccination in patients with mast cell disease, patients who developed an allergy during the first dose, vasovagal symptoms masquerading as allergic reactions, the COVID-19 vaccination in pregnancy, deaths associated with COVID-19 vaccination, and questions arising in managing of this current ordeal. Careful vaccine-safety surveillance over time, in conjunction with the elucidation of mechanisms of adverse events across different COVID-19 vaccine platforms, will contribute to the development of a safe vaccine strategy. Allergists’ expertise in proper diagnosis and treatment of allergic reactions is vital for the screening of high-risk individuals.

1 January 2017 in Journal of Clinical Medicine Research
Verified
Journal Article
Open access
DVDimitrios Velissaris
Dimitrios Velissaris
NPNikolaos Pantzaris
Nikolaos Pantzaris
IKIoanna Koniari
Ioanna Koniari
NKNikolaos Koutsogiannis
Nikolaos Koutsogiannis
VKVasileios Karamouzos
Vasileios Karamouzos
JEJohn Ellul
John Ellul
Chronic inflammation is a well-established background process in many age-related diseases. Many recent studies investigate the use of various inflammatory biomarkers such as C-reactive protein (CRP), interleukin-6, and interleukin-1 as predictors of physical and cognitive performance among elders. The phenotype of frailty has also been associated with underlying inflammatory mechanisms. The aim of this article was to review the literature referring to the correlation of CRP serum levels and frailty in older individuals. We tried to identify all relevant publications regarding the relation of CRP as an index of frailty in the elderly and its potential use. Although many studies in the recent medical literature positively associate serum CRP levels and frailty in older individuals, some do not, and some raise some interesting questions and set the basis for future studies. The association of CRP and frailty in elder patients should be considered when clinicians interpret inflammatory biomarkers in various clinical settings in such patients. Well-designed, prospective clinical trials are warranted to better assess the role and pathophysiology of frailty in the elderly and its mechanisms as also the exact role of CRP as an inflammatory marker and as a prognostic index in this syndrome.

25 May 2010 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
CEC. E. Eapen
C. E. Eapen
PNPeter Nightingale
Peter Nightingale
SHStefan Hubscher
Stefan Hubscher
PLPeter J. Lane
Peter J. Lane
TPTimothy Plant
Timothy Plant
EEElwyn Elias
Elwyn Elias

13 May 2021 in Cureus
Verified
Journal Article
Open access
DVDimitrios Velissaris
Dimitrios Velissaris
NZNicholas Zareifopoulos
Nicholas Zareifopoulos
VKVasileios Karamouzos
Vasileios Karamouzos
EKEvangelos Karanikolas
Evangelos Karanikolas
CPCharalampos Pierrakos
Charalampos Pierrakos
MKMenelaos Karanikolas
Menelaos Karanikolas
Sepsis is a condition characterized by high morbidity and mortality which is commonly encountered in an emergency and critical care setting. Despite a substantial body of research, the ideal biomarker for the diagnosis and prognostic stratification of septic patients remains unknown. This review aimed to summarize the publications referring to the validity of the biomarker presepsin when used for the detection, monitoring and prognosis in patients suffering with sepsis. This work is a narrative review based on a PubMed/Medline search conducted in order to identify all relevant publications referring to the use of presepsin in sepsis. Search was not limited by year of publication so all articles archived in the database would be retrieved. No article from before 2010 was identified. A total of 57 publications of the last decade were included, all of which support the use of presepsin as a biomarker for the assessment of septic patients. It has been used alone or in combination with commonly used biomarkers in the evaluation of patients with sepsis in settings such as the emergency department and the intensive care unit. It is useful in the initial workup of patients with suspected sepsis in the emergency setting and may be a predictive factor of mortality and the most severe complication of sepsis. Presepsin seems to be a valuable tool for the laboratory workup of sepsis, especially when used in conjunction with other biomarkers and clinical rating scores with an established role in this population. Further research is needed to evaluate the clinical implications of utilizing presepsin measurements in the workup of sepsis.

1 October 2018 in Journal of Critical Care
Verified
Journal Article
Closed access
Loukas KakoullisLoukas Kakoullis
Loukas Kakoullis
NPNikolaos-Dimitrios Pantzaris
Nikolaos-Dimitrios Pantzaris
CPChiristina Platanaki
Chiristina Platanaki
MLMARIA LAGADINOU
MARIA LAGADINOU
EPEleni Papachristodoulou
Eleni Papachristodoulou
DVDimitrios Velissaris
Dimitrios Velissaris

1 January 2013 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
CPCharalampos Pierrakos
Charalampos Pierrakos
AAAurélie Antoine
Aurélie Antoine
DVDimitrios Velissaris
Dimitrios Velissaris
IMIsabelle Michaux
Isabelle Michaux
PBPierre Bulpa
Pierre Bulpa
ADAlain Dive
Alain Dive
The aim of this study is to evaluate the feasibility and efficacy of Transcranial Doppler (TCD) in assessing cerebral perfusion changes in septic patients.